4.6 Article

Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice

Journal

MICROBES AND INFECTION
Volume 16, Issue 6, Pages 512-517

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.micinf.2014.02.011

Keywords

Bacteriophage; Mouse; Podoviridae; Therapeutic; Therapy

Funding

  1. Center for Innovative and Translational Medicine, Kochi System Glycobiology Center [24791025]
  2. Center of Biomembrane Functions Controlling Biological Systems, Kochi University, Kochi, Japan
  3. Grants-in-Aid for Scientific Research [26461504, 23591478, 24791025] Funding Source: KAKEN

Ask authors/readers for more resources

Nosocomial respiratory infections caused by methicillin-resistant Staphylococcus aureus (MRSA) can progress to lethal systemic infections. Bacteriophage (phage) therapy is expected to be effective against these critical infections. Previously, phage S13' was proposed as a potential therapeutic phage. We here examined phage treatment in a mouse model of lung-derived septicemia using phage S13'. Intraperitoneal phage administration at 6 h postinfection reduced the severity of infection and rescued the infected mice. Phage S13' can efficiently lyse hospital-acquired MRSA strains causing pneumonia-associated bacterernia in vitro. Thus, phage therapy may be a possible therapeutic intervention in staphylococcal lung-derived septicemia. (C) 2014 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available